LEXICON PHARMACEUTICALS, INC. Deferred Tax Assets, Deferred Income
LEXICON PHARMACEUTICALS, INC. (LXRX) had Deferred Tax Assets, Deferred Income of $0 as of 2019-12-31, per its 10-K filed 2020-03-12.
Discontinued › Notes › Income Taxes › Deferred Tax Assets, Gross
us-gaap:DeferredTaxAssetsDeferredIncome · last filed 2020-03-12
- 2019-12-31: Deferred Tax Assets, Deferred Income $0.00.
- 2018-12-31: Deferred Tax Assets, Deferred Income $5.46M.
- 2017-12-31: Deferred Tax Assets, Deferred Income $13.52M; Deferred Tax Assets, Deferred Income as first filed $12.95M.
- 2016-12-31: Deferred Tax Assets, Deferred Income $39.31M.
| Period end | Deferred Tax Assets, Deferred Income | Deferred Tax Assets, Deferred Income as first filed |
|---|---|---|
| 2019-12-31 | $0.00 10-K · filed 2020-03-12 | |
| 2018-12-31 | $5.46M 10-K · filed 2020-03-12 | |
| 2017-12-31 | $13.52M 10-K · filed 2019-03-15 | $12.95M 10-K · filed 2018-03-01 |
| 2016-12-31 | $39.31M 10-K · filed 2018-03-01 | |
| 2015-12-31 | $4.36M 10-K · filed 2017-03-06 | |
| 2014-12-31 | $4.46M 10-K · filed 2016-03-11 | |
| 2013-12-31 | $4.76M 10-K · filed 2015-03-12 | |
| 2012-12-31 | $4.91M 10-K · filed 2014-03-07 | |
| 2011-12-31 | $5.01M 10-K · filed 2013-03-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |